Evidence map›Paper›PMID 40181912›Full record

ArticleAIMS molecular science2017

Calpain inhibition as a possible new therapeutic target in multiple sclerosis.

Amena W Smith, Swapan K Ray, Arabinda Das, Kenkichi Nozaki, Baerbel Rohrer, Naren L Banik

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIMS molecular science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Amena W SmithDepartment of Neurosciences, Medical University of South Carolina, Charleston, SC, USA.
Swapan K RayDepartment of Pathology, Microbiology and Immunology, University of South Carolina, Columbia, SC, USA.
Arabinda DasDepartment of Neurosurgery, Medical University of South Carolina, Charleston, SC, USA.
Kenkichi NozakiDepartment of Neurosciences, Medical University of South Carolina, Charleston, SC, USA.
Baerbel RohrerDepartment of Ophthalmology, Medical University of South Carolina, Charleston, SC, USA.
Naren L BanikDepartment of Neurosurgery, Medical University of South Carolina, Charleston, SC, USA.

Funding

Attenuation of Axonal Damage and Neuronal Death in EAER01NS056176 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BANIK, NAREN L · 2006 to 2010
$1.6M
Inflammation and Degeneration of Optic Nerve in EAER01NS065456 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BANIK, NAREN L · 2009 to 2013
$1.6M
NINDS NIH HHS R01 NS056176NINDS NIH HHS R01 NS065456
6 · The paper itself

Abstract

Multiple sclerosis (MS), the most common chronic autoimmune inflammatory disease of the central nervous system (CNS), is characterized by demyelination and neurodegeneration. In particular, neurodegeneration is a major factor in disease progression with neuronal death and irreversible axonal damage leading to disability. MS is manageable with current therapies that are directed towards immunomodulation but there are no available therapies for neuroprotection. The complex pathophysiology and heterogeneity of MS indicate that therapeutic agents should be directed to both the inflammatory and neurodegenerative arms of the disease. Activity of the Ca

Indexed as

axonal degenerationcalpaincalpain inhibitiondemyelinationinflammationneurodegenerationneuronsoligodendrocytesoptic neuritisretinal ganglion cells

Identifiers

PMID40181912
PMCPMC11967729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.